| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 20 | 2024 | 115 | 5.460 |
Why?
|
| Papillomavirus Infections | 17 | 2024 | 74 | 4.290 |
Why?
|
| Cervical Intraepithelial Neoplasia | 11 | 2021 | 36 | 4.120 |
Why?
|
| HIV Infections | 46 | 2024 | 5097 | 3.280 |
Why?
|
| Papillomaviridae | 10 | 2020 | 34 | 2.480 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 131 | 2.270 |
Why?
|
| Early Detection of Cancer | 7 | 2024 | 39 | 1.970 |
Why?
|
| Papillomavirus Vaccines | 5 | 2021 | 18 | 1.900 |
Why?
|
| Papanicolaou Test | 7 | 2024 | 29 | 1.890 |
Why?
|
| Female | 59 | 2024 | 9103 | 1.730 |
Why?
|
| Adult | 48 | 2024 | 5913 | 1.660 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2024 | 9 | 1.560 |
Why?
|
| HIV Seropositivity | 8 | 2017 | 265 | 1.500 |
Why?
|
| Humans | 66 | 2024 | 14537 | 1.480 |
Why?
|
| South Africa | 40 | 2021 | 7596 | 1.340 |
Why?
|
| Colposcopy | 4 | 2024 | 17 | 1.310 |
Why?
|
| Quality Assurance, Health Care | 5 | 2017 | 43 | 1.290 |
Why?
|
| Middle Aged | 27 | 2024 | 3601 | 1.220 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 9 | 2019 | 226 | 1.210 |
Why?
|
| Cryotherapy | 2 | 2017 | 5 | 1.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2020 | 472 | 1.110 |
Why?
|
| Rifampin | 9 | 2021 | 197 | 1.040 |
Why?
|
| Optical Imaging | 2 | 2015 | 2 | 0.980 |
Why?
|
| Mammography | 1 | 2024 | 3 | 0.920 |
Why?
|
| Vaginal Smears | 4 | 2024 | 34 | 0.910 |
Why?
|
| Antitubercular Agents | 7 | 2021 | 322 | 0.860 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 17 | 0.800 |
Why?
|
| HIV-1 | 12 | 2020 | 1260 | 0.790 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 8 | 0.770 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 256 | 0.720 |
Why?
|
| Anti-HIV Agents | 12 | 2020 | 1324 | 0.720 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2017 | 132 | 0.700 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2019 | 47 | 0.700 |
Why?
|
| Cost-Benefit Analysis | 5 | 2018 | 253 | 0.690 |
Why?
|
| Prevalence | 13 | 2018 | 1192 | 0.670 |
Why?
|
| Antibodies, Viral | 4 | 2018 | 284 | 0.650 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 1 | 0.630 |
Why?
|
| Breast | 1 | 2018 | 10 | 0.630 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 280 | 0.630 |
Why?
|
| Access to Information | 1 | 2018 | 2 | 0.620 |
Why?
|
| Contraceptive Agents, Female | 2 | 2020 | 47 | 0.600 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 125 | 0.600 |
Why?
|
| Male | 22 | 2019 | 6754 | 0.580 |
Why?
|
| Electrosurgery | 1 | 2017 | 3 | 0.570 |
Why?
|
| Oncology Service, Hospital | 1 | 2017 | 3 | 0.560 |
Why?
|
| Hepatitis B | 2 | 2008 | 125 | 0.550 |
Why?
|
| Mass Screening | 5 | 2024 | 245 | 0.550 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2018 | 656 | 0.550 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 62 | 0.540 |
Why?
|
| Anus Neoplasms | 2 | 2015 | 4 | 0.540 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 32 | 0.540 |
Why?
|
| Health Resources | 1 | 2017 | 66 | 0.530 |
Why?
|
| Treatment Outcome | 10 | 2024 | 889 | 0.530 |
Why?
|
| United States | 7 | 2024 | 132 | 0.530 |
Why?
|
| Coinfection | 6 | 2024 | 276 | 0.520 |
Why?
|
| Precancerous Conditions | 4 | 2020 | 10 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 262 | 0.510 |
Why?
|
| Surgical Instruments | 1 | 2015 | 11 | 0.510 |
Why?
|
| Young Adult | 15 | 2018 | 2498 | 0.510 |
Why?
|
| Trichomonas vaginalis | 2 | 2012 | 5 | 0.510 |
Why?
|
| Retrospective Studies | 8 | 2021 | 799 | 0.500 |
Why?
|
| Aged | 8 | 2019 | 1740 | 0.490 |
Why?
|
| Women's Health Services | 1 | 2015 | 12 | 0.490 |
Why?
|
| Mobile Health Units | 1 | 2015 | 7 | 0.490 |
Why?
|
| Sensitivity and Specificity | 7 | 2017 | 385 | 0.480 |
Why?
|
| Specimen Handling | 1 | 2015 | 105 | 0.480 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2013 | 187 | 0.480 |
Why?
|
| Rural Health Services | 1 | 2015 | 48 | 0.470 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 118 | 0.470 |
Why?
|
| Urban Population | 3 | 2018 | 257 | 0.460 |
Why?
|
| Disease Progression | 4 | 2016 | 154 | 0.440 |
Why?
|
| Prospective Studies | 7 | 2019 | 1160 | 0.430 |
Why?
|
| Tuberculosis | 5 | 2021 | 543 | 0.420 |
Why?
|
| Genital Neoplasms, Male | 1 | 2012 | 1 | 0.410 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2012 | 4 | 0.410 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 3 | 0.410 |
Why?
|
| Viral Load | 8 | 2020 | 819 | 0.410 |
Why?
|
| Uterine Cervicitis | 1 | 2012 | 1 | 0.410 |
Why?
|
| Mycoplasma genitalium | 1 | 2012 | 1 | 0.410 |
Why?
|
| Urethritis | 1 | 2012 | 2 | 0.410 |
Why?
|
| Chlamydia trachomatis | 1 | 2012 | 13 | 0.410 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2012 | 15 | 0.410 |
Why?
|
| Adolescent | 12 | 2018 | 2985 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 239 | 0.400 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2008 | 48 | 0.390 |
Why?
|
| Cervix Uteri | 3 | 2024 | 22 | 0.380 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 23 | 0.380 |
Why?
|
| Penile Diseases | 1 | 2011 | 2 | 0.370 |
Why?
|
| Condylomata Acuminata | 1 | 2011 | 4 | 0.370 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 529 | 0.370 |
Why?
|
| Neutropenia | 1 | 2010 | 9 | 0.360 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 11 | 0.360 |
Why?
|
| Health Care Costs | 4 | 2018 | 115 | 0.350 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 195 | 0.350 |
Why?
|
| Anemia | 1 | 2010 | 41 | 0.350 |
Why?
|
| Anti-Retroviral Agents | 5 | 2021 | 551 | 0.350 |
Why?
|
| Risk Factors | 7 | 2017 | 1475 | 0.350 |
Why?
|
| Women's Health | 1 | 2009 | 41 | 0.330 |
Why?
|
| Health Status | 1 | 2009 | 111 | 0.320 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 50 | 0.310 |
Why?
|
| Anal Canal | 2 | 2018 | 7 | 0.300 |
Why?
|
| Vaccination | 3 | 2021 | 365 | 0.300 |
Why?
|
| Diarylquinolines | 2 | 2018 | 39 | 0.290 |
Why?
|
| DNA, Viral | 3 | 2018 | 165 | 0.290 |
Why?
|
| Comorbidity | 3 | 2016 | 188 | 0.270 |
Why?
|
| Human Papillomavirus DNA Tests | 2 | 2017 | 4 | 0.260 |
Why?
|
| Atazanavir Sulfate | 2 | 2016 | 10 | 0.260 |
Why?
|
| Acetic Acid | 2 | 2016 | 3 | 0.250 |
Why?
|
| Tenofovir | 2 | 2017 | 171 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 16 | 0.230 |
Why?
|
| Incidence | 4 | 2017 | 685 | 0.230 |
Why?
|
| Laboratories | 2 | 2015 | 47 | 0.230 |
Why?
|
| Outpatients | 1 | 2024 | 38 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2016 | 135 | 0.230 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2021 | 44 | 0.230 |
Why?
|
| Zidovudine | 2 | 2015 | 59 | 0.210 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 34 | 0.210 |
Why?
|
| Developing Countries | 4 | 2018 | 400 | 0.210 |
Why?
|
| Lamivudine | 2 | 2015 | 89 | 0.210 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 1422 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 151 | 0.200 |
Why?
|
| Time Factors | 4 | 2018 | 507 | 0.200 |
Why?
|
| HIV | 2 | 2021 | 380 | 0.190 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 435 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A Inducers | 1 | 2021 | 1 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2021 | 3 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2021 | 11 | 0.190 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2018 | 2 | 0.190 |
Why?
|
| Human papillomavirus 18 | 2 | 2011 | 7 | 0.180 |
Why?
|
| Human papillomavirus 16 | 2 | 2011 | 7 | 0.180 |
Why?
|
| Sex Factors | 3 | 2018 | 227 | 0.180 |
Why?
|
| Glycomics | 1 | 2020 | 2 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 370 | 0.170 |
Why?
|
| Drug Combinations | 2 | 2021 | 42 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2019 | 329 | 0.170 |
Why?
|
| Alkynes | 2 | 2021 | 117 | 0.170 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2019 | 35 | 0.170 |
Why?
|
| Cyclopropanes | 2 | 2021 | 123 | 0.170 |
Why?
|
| Benzoxazines | 2 | 2021 | 123 | 0.160 |
Why?
|
| Urban Health Services | 1 | 2019 | 10 | 0.160 |
Why?
|
| Gene Expression | 1 | 2019 | 43 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2019 | 30 | 0.160 |
Why?
|
| Lopinavir | 3 | 2021 | 137 | 0.160 |
Why?
|
| Ritonavir | 3 | 2021 | 137 | 0.160 |
Why?
|
| Africa, Southern | 2 | 2016 | 91 | 0.160 |
Why?
|
| Uterus | 1 | 2018 | 20 | 0.160 |
Why?
|
| Brazil | 3 | 2016 | 47 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 112 | 0.160 |
Why?
|
| Menopause | 1 | 2018 | 24 | 0.160 |
Why?
|
| Age Factors | 3 | 2018 | 370 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2018 | 80 | 0.150 |
Why?
|
| South America | 3 | 2016 | 27 | 0.150 |
Why?
|
| Africa | 3 | 2020 | 376 | 0.150 |
Why?
|
| Income | 1 | 2018 | 85 | 0.150 |
Why?
|
| Prognosis | 3 | 2020 | 199 | 0.150 |
Why?
|
| Anus Diseases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Herpes Simplex | 1 | 2017 | 7 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 15 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.140 |
Why?
|
| Herpesvirus 2, Human | 1 | 2017 | 43 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.140 |
Why?
|
| Sputum | 2 | 2016 | 135 | 0.140 |
Why?
|
| Pregnancy | 3 | 2020 | 1862 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2017 | 111 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 80 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 563 | 0.130 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2016 | 1 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2016 | 2 | 0.130 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2016 | 5 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 34 | 0.130 |
Why?
|
| Cytisus | 1 | 2015 | 2 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 31 | 0.130 |
Why?
|
| RNA, Viral | 2 | 2020 | 303 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 57 | 0.130 |
Why?
|
| Cognition | 1 | 2016 | 75 | 0.120 |
Why?
|
| Contraception | 1 | 2016 | 90 | 0.120 |
Why?
|
| Asia | 2 | 2016 | 72 | 0.120 |
Why?
|
| Emtricitabine | 1 | 2015 | 78 | 0.120 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 42 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 2 | 2018 | 303 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 44 | 0.110 |
Why?
|
| Stavudine | 2 | 2012 | 78 | 0.110 |
Why?
|
| Markov Chains | 3 | 2018 | 22 | 0.110 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2014 | 7 | 0.110 |
Why?
|
| Mycobacterium | 1 | 2014 | 16 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 103 | 0.110 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2017 | 196 | 0.110 |
Why?
|
| Health Personnel | 1 | 2016 | 231 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 54 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2015 | 240 | 0.100 |
Why?
|
| Trichomonas Vaginitis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.100 |
Why?
|
| Antiprotozoal Agents | 1 | 2012 | 7 | 0.100 |
Why?
|
| Autoantigens | 1 | 2012 | 10 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2012 | 21 | 0.100 |
Why?
|
| Virus Shedding | 1 | 2012 | 24 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2016 | 324 | 0.100 |
Why?
|
| Demography | 1 | 2013 | 105 | 0.100 |
Why?
|
| Internationality | 1 | 2012 | 36 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 42 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 217 | 0.100 |
Why?
|
| Vagina | 1 | 2012 | 91 | 0.100 |
Why?
|
| Human papillomavirus 11 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Human papillomavirus 6 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Algorithms | 1 | 2012 | 106 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2017 | 967 | 0.100 |
Why?
|
| Botswana | 1 | 2011 | 24 | 0.100 |
Why?
|
| Biopsy | 2 | 2024 | 38 | 0.100 |
Why?
|
| Vaginosis, Bacterial | 1 | 2011 | 19 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 260 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 1 | 2011 | 109 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 12 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2012 | 215 | 0.090 |
Why?
|
| Caribbean Region | 1 | 2010 | 11 | 0.090 |
Why?
|
| Americas | 1 | 2010 | 10 | 0.090 |
Why?
|
| Delayed-Action Preparations | 2 | 2021 | 68 | 0.090 |
Why?
|
| Leptin | 1 | 2010 | 26 | 0.090 |
Why?
|
| Child | 2 | 2016 | 2242 | 0.090 |
Why?
|
| Adiposity | 1 | 2011 | 96 | 0.090 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 2009 | 3 | 0.080 |
Why?
|
| Genotype | 1 | 2011 | 442 | 0.080 |
Why?
|
| Liver | 1 | 2008 | 74 | 0.080 |
Why?
|
| Drug Costs | 2 | 2018 | 18 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2008 | 225 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 156 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 163 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 244 | 0.060 |
Why?
|
| Contraceptive Effectiveness | 1 | 2021 | 2 | 0.050 |
Why?
|
| Nelfinavir | 1 | 2021 | 6 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2021 | 31 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 110 | 0.040 |
Why?
|
| Reference Standards | 1 | 2020 | 29 | 0.040 |
Why?
|
| Virus Replication | 1 | 2020 | 88 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 41 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 193 | 0.040 |
Why?
|
| Atrophy | 1 | 2018 | 6 | 0.040 |
Why?
|
| Biomarkers | 1 | 2020 | 327 | 0.040 |
Why?
|
| Ethiopia | 1 | 2018 | 18 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2018 | 15 | 0.040 |
Why?
|
| Employment | 1 | 2018 | 27 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 34 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 198 | 0.040 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 2 | 0.040 |
Why?
|
| Proctoscopy | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 2 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 21 | 0.040 |
Why?
|
| Seroconversion | 1 | 2017 | 5 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 34 | 0.040 |
Why?
|
| International Cooperation | 1 | 2017 | 50 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 8 | 0.030 |
Why?
|
| Verbal Learning | 1 | 2016 | 3 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 18 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 64 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 53 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 13 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 68 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 151 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 99 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 92 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 306 | 0.030 |
Why?
|
| Pathology | 1 | 2013 | 2 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 11 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 10 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 40 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2012 | 26 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 279 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 37 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 85 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 67 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 353 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 16 | 0.020 |
Why?
|
| Glucose | 1 | 2010 | 45 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 7 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 17 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 39 | 0.020 |
Why?
|